- Raw materials
- Antibacterials
- Nitrocefin
Nitrocefin API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Nitrocefin | CAS No: 41906-86-9 | GMP-certified suppliers
A medication that serves as a diagnostic reagent for rapid detection of beta-lactamase enzymes, aiding differentiation of antibiotic-resistant bacterial strains in research and clinical settings.
Therapeutic categories
Product Snapshot
- Nitrocefin is a beta-lactam antibiotic substrate primarily used for enzymatic assays
- It is utilized in research applications to detect beta-lactamase activity
- Nitrocefin currently holds experimental status and is not approved for therapeutic use in major regulatory markets
Clinical Overview
Structurally, nitrocefin belongs to the cephalosporin class, characterized by a fused 1,2-thiazine and 2-azetidinone ring system forming an oxo-5-thia-1-azabicyclooct-2-ene-2-carboxylic acid scaffold or its derivative. This framework mimics the native beta-lactam antibiotic core, allowing selective interaction with beta-lactamase enzymes. Upon enzymatic hydrolysis of the beta-lactam ring, nitrocefin undergoes a distinct color change from yellow to red, which is detectable using minimal instrumentation.
Nitrocefin has no direct therapeutic indication and is utilized exclusively in research, clinical microbiology laboratories, and industrial contexts for phenotypic screening of beta-lactamase production. Alternative methods for detecting beta-lactamase include molecular techniques such as polymerase chain reaction (PCR); however, nitrocefin offers the advantage of rapid results without complex equipment.
Pharmacokinetic and toxicity profiles are not applicable in the context of nitrocefin’s intended use as it is employed as an in vitro reagent. Nonetheless, appropriate handling and disposal procedures should be followed due to its chemical composition, which includes sulfur heterocycles and beta-lactam structures.
Currently, nitrocefin is classified as an experimental compound and is not approved for therapeutic applications. When procuring nitrocefin as an active pharmaceutical ingredient (API) or reagent, quality considerations focus on reagent purity, stability, and batch-to-batch consistency to ensure reliable enzymatic assay performance. Suppliers should provide certificates of analysis demonstrating adherence to relevant chemical and microbiological purity standards.
Identification & chemistry
| Generic name | Nitrocefin |
|---|---|
| Molecule type | Small molecule |
| CAS | 41906-86-9 |
| UNII | EWP54G0J8F |
| DrugBank ID | DB11592 |
Formulation & handling
- Nitrocefin is a small molecule cephalosporin with low water solubility, requiring careful formulation to enhance bioavailability.
- The solid state and moderate LogP suggest potential suitability for oral dosage forms, though solubility may limit absorption.
- Stability handling considerations should include protection from moisture due to its limited aqueous solubility and potential hydrolysis.
Regulatory status
Nitrocefin is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
